The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 16, 2020
Filed:
Sep. 15, 2017
Applicants:
Kissei Pharmaceutical Co., Ltd., Matsumoto-shi, Nagano, JP;
Shinshu University, Matsumoto-shi, Nagano, JP;
Inventors:
Assignees:
KISSEI PHARMACEUTICAL CO., LTD., Matsumoto-shi, Nagano, JP;
SHINSHU UNIVERSITY, Matsumoto-shi, Nagano, JP;
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 48/00 (2006.01); C07K 16/30 (2006.01); C07K 19/00 (2006.01); C12N 5/0783 (2010.01); C07K 16/28 (2006.01); A61K 31/7088 (2006.01); C12N 5/10 (2006.01); C07K 16/24 (2006.01); C07K 14/535 (2006.01); A61K 35/12 (2015.01); A61P 43/00 (2006.01); A61P 35/00 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); C12N 15/113 (2010.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); A61K 31/7088 (2013.01); A61K 35/12 (2013.01); A61K 35/17 (2013.01); A61K 39/001139 (2018.08); A61K 48/00 (2013.01); A61P 35/00 (2018.01); A61P 43/00 (2018.01); C07K 14/535 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/243 (2013.01); C07K 19/00 (2013.01); C12N 5/0636 (2013.01); C12N 5/10 (2013.01); C12N 15/1136 (2013.01); A61K 38/00 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/572 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C12N 2310/122 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2510/00 (2013.01);
Abstract
Production of a chimeric antigen receptor (CAR) expressing cell having excellent target cytotoxicity. Provided is a genetically modified cell comprising, introduced thereinto, a polynucleotide encoding a chimeric antigen receptor (CAR) protein having a target binding domain that specifically binds to a human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor, a transmembrane domain and an intracellular signaling domain.